CHDR to conduct first-in-human phase 1 trial of IMP761
Filed with ASX · · 2 pages · English
Earlier from Immutep
- First Clinical Data announced from 90mg Dosing of Efti
- PEI provides constructive feedback for ph3 lung cancer trial
- Immutep receives A$2.6 million French R&D Tax Incentive
- Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
- Lead-in phase completed for ph2/3 trial in Breast Cancer
Later from Immutep
- Positive preliminary topline results from TACTI-003 Cohort B
- Positive initial data in phase 2 Soft Tissue Sarcoma trial
- AIPAC-003 safety lead-in data presented at ESMO Breast 2024
- A$100 million fully underwritten equity raising
- Immutep Capital Raising Presentation
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep